Barely Significant
← all excerpts

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.

Acta Biomed · 2018 · PMC6502110 · PMID 30333452

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp<0.001actually significant
As reported in ASTRAL-3, HCV GT3 infected patients treated with SOF/VEL for 12 weeks reached a 95% SVR rate compared to 80% as shown by those receiving SOF plus RBV for 24 weeks, which is a highly significant difference in efficacy (p<0.001) ( 10 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.